Patents by Inventor Venkata Palle

Venkata Palle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polymorphic forms of Dasatinib
    Patent number: 11059813
    Abstract: The present invention provides for the dasatinib-thymine co-crystal and dasatinib-adenine co-crystal. The present invention further provides dasatinib-butanediol solvate. The present invention further provides for crystalline dasatinib-(±)-1, 2-Butanediol, crystalline dasatinib (R)-1, 2-Butanediol, crystalline dasatinib (S)-1, 2-Butanediol and crystalline dasatinib (±)-2, 3-Butanediol and processes for preparation thereof. The present invention also provides for a process for preparation of amorphous dasatinib using dasatinib-butanediol solvate. The present invention further provides for the preparation of anhydrous dasatinib. The present invention also provides for a process for preparation of dasatinib monohydrate from anhydrous dasatinib.
    Type: Grant
    Filed: July 7, 2018
    Date of Patent: July 13, 2021
    Assignee: BIOCON LIMITED
    Inventors: Ramakrishna Parameshwar Bhat, Jithendrababu Raghunadhachetty, Raghavendracharyulu Venkata Palle, Mariappan Kaliappan, Reddy VijayBhaskar Regalla
  • POLYMORPHIC FORMS OF DASATINIB
    Publication number: 20200377495
    Abstract: The present invention provides for the dasatinib-thymine co-crystal and dasatinib-adenine co-crystal. The present invention further provides dasatinib-butanediol solvate. The present invention further provides for crystalline dasatinib-(±)-1,2-Butane diol, crystalline dasatinib (R)-1,2-Butanediol, crystalline dasatinib (S)-1,2-Butanediol and crystalline dasatinib (±)-2,3-Butanediol and processes for preparation thereof. The present invention also provides for a process for preparation of amorphous dasatinib using dasatinib-butanediol solvate. The present invention further provides for the preparation of anhydrous dasatinib.
    Type: Application
    Filed: July 7, 2018
    Publication date: December 3, 2020
    Applicant: Biocon Limited
    Inventors: Ramakrisna Parameshwar BHAT, Jithendrababu RAGHUNADHACHETTY, Raghavendracharyulu Venkata PALLE, Mariappan KALIAPPAN, Reddy VijayBhaskar REGALLA
  • Glycoside derivatives and uses thereof
    Patent number: 9895389
    Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: February 20, 2018
    Assignee: Novartis AG
    Inventors: Gregory Raymond Bebernitz, Mark G. Bock, Dumbala Srinivas Reddy, Atul Kashinath Hajare, Vinod Vyavahare, Sandeep Bhausaheb Bhosale, Suresh Eknath Kurhade, Videsh Salunkhe, Nadim S. Shaikh, Debnath Bhuniya, P. Venkata Palle, Lili Feng, Jessica Liang
  • GLYCOSIDE DERIVATIVES AND USES THEREOF
    Publication number: 20170042925
    Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
    Type: Application
    Filed: April 20, 2016
    Publication date: February 16, 2017
    Inventors: Gregory Raymond Bebernitz, Mark G. Bock, Dumbala Srinivas Reddy, Atul Kashinath Hajare, Vinod Vyavahare, Sandeep Bhausaheb Bhosale, Suresh Eknath Kurhade, Videsh Salunkhe, Nadim S. Shaikh, Debnath Bhuniya, P. Venkata Palle, Lili Feng, Jessica Liang
  • Substituted fused pyrimidine compounds
    Patent number: 9284316
    Abstract: The present invention discloses substituted fused pyrimidine compounds of formula (I), their tautomers, polymorphs, stereoisomers, solvates, pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity; the compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor, such as asthma, chronic obstructive pulmonary disorder, angiogenesis, pulmonary fibrosis, emphysema, allergic diseases, inflammation, reperfusion injury, myocardial ischemia, atherosclerosis, hypertension, congestive heart failure, retinopathy, diabetes mellitus, obesity, inflammatory gastrointestinal tract disorders, and/or autoimmune diseases.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: March 15, 2016
    Assignee: Advinus Therapeutics Private Limited
    Inventors: Venkata Palle, Vidya Ramdas, Dinesh Barawkar, Sujay Basu, Summon Koul, Yogesh Waman, Meena Patel, Anil Panmand
  • GLYCOSIDE DERIVATIVES AND USES THEREOF
    Publication number: 20150141354
    Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 21, 2015
    Applicant: NOVARTIS AG
    Inventors: Gregory Raymond BEBERNITZ, Mark G. BOCK, Dumbala Srinivas REDDY, Atul Kashinath HAJARE, Vinod VYAVAHARE, Sandeep Bhausaheb BHOSALE, Suresh Eknath KURHADE, Videsh SALUNKHE, Nadim S. SHAIKH, Debnath BHUNIYA, P. Venkata PALLE, Lili FENG, Jessica LIANG
  • Substituted Fused Pyrimidine Compounds
    Publication number: 20150087643
    Abstract: The present invention discloses substituted fused pyrimidine compounds of formula (I), their tautomers, polymorphs, stereoisomers, solvates, pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity; the compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor, such as asthma, chronic obstructive pulmonary disorder, angiogenesis, pulmonary fibrosis, emphysema, allergic diseases, inflammation, reperfusion injury, myocardial ischemia, atherosclerosis, hypertension, congestive heart failure, retinopathy, diabetes mellitus, obesity, inflammatory gastrointestinal tract disorders, and/or autoimmune diseases.
    Type: Application
    Filed: October 10, 2014
    Publication date: March 26, 2015
    Applicant: Advinus Therapeutics Private Limited
    Inventors: Venkata Palle, Vidya Ramdas, Dinesh Barawkar, Sujay Basu, Summon Koul, Yogesh Waman, Meena Patel, Anil Panmand
  • Substituted fused pyrimidine compounds
    Patent number: 8859566
    Abstract: The present invention discloses substituted fused pyrimidine compounds of formula (I), their tautomers, polymorphs, stereoisomers, solvates, pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor, such as asthma, chronic obstructive pulmonary disorder, angiogenesis, pulmonary fibrosis, emphysema, allergic diseases, inflammation, reperfusion injury, myocardial ischemia, atherosclerosis, hypertension, congestive heart failure, retinopathy, diabetes mellitus, obesity, inflammatory gastrointestinal tract disorders, and/or autoimmune diseases.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: October 14, 2014
    Assignee: Advinus Therapeutics Private Limited
    Inventors: Venkata Palle, Vidya Ramdas, Dinesh Barawkar, Sujay Basu, Summon Koul, Yogesh Waman, Meena Patel, Anil Panmand
  • GLYCOSIDE DERIVATIVES AND USES THEREOF
    Publication number: 20140274921
    Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
    Type: Application
    Filed: May 30, 2014
    Publication date: September 18, 2014
    Applicant: NOVARTIS AG
    Inventors: Gregory Raymond BEBERNITZ, Mark G. BOCK, Dumbala Srinivas REDDY, Atul Kashinath HAJARE, Vinod VYAVAHARE, Sandeep Bhausaheb BHOSALE, Suresh Eknath KURHADE, Videsh SALUNKHE, Nadim S. SHAIKH, Debnath BHUNIYA, P. Venkata PALLE, Lili FENG, Jessica LIANG
  • Glycoside derivatives and uses thereof
    Patent number: 8828951
    Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: September 9, 2014
    Assignee: Novartis AG
    Inventors: Gregory Raymond Bebernitz, Mark G. Bock, Dumbala Srinivas Reddy, Atul Kashinath Hajare, Vinod Vyavahare, Sandeep Bhausaheb Bhosale, Suresh Eknath Kurhade, Videsh Salunkhe, Nadim S. Shaikh, Debnath Bhuniya, P. Venkata Palle, Lili Feng, Jessica Liang
  • SOLID FORMS OF PEMETREXED
    Publication number: 20140066463
    Abstract: There is provided polymorphs and amorphous form of pemetrexed or its pharmaceutical acceptable salts and process for making thereof.
    Type: Application
    Filed: April 5, 2013
    Publication date: March 6, 2014
    Applicants: DR. REDDY'S LABORATORIES, INC., DR. REDDY'S LABORATORIES LTD.
    Inventors: Raghavendracharyulu Venkata Palle, Sekhar Munaswamy Nariyam, Vijay Bhailalbhai Patel, Raghupati Rama Subrahmanyam Vinjamuri, Surya Narayana Devarakonda, Sesha Reddy Yarraguntla, Vamsi Krishna Mudapaka, Venu Nalivela
  • Process for the purification of palonosetron or its salt
    Patent number: 8614225
    Abstract: The present application relates to a process for purification of palonosetron or its salt substantially free of its R-isomer and structure related impurities.
    Type: Grant
    Filed: August 28, 2007
    Date of Patent: December 24, 2013
    Assignees: Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.
    Inventors: Raghavendracharyulu Venkata Palle, Madhavrao Marathe Anant, Nageshwar Gunda
  • Solid forms of pemetrexed
    Patent number: 8507508
    Abstract: There is provided polymorphs and amorphous form of pemetrexed or its pharmaceutical acceptable salts and process for making thereof.
    Type: Grant
    Filed: April 4, 2008
    Date of Patent: August 13, 2013
    Assignees: Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.
    Inventors: Raghavendracharyulu Venkata Palle, Sekhar Munaswamy Nariyam, Vijay Bhailalbhai Patel, Raghupati Rama Subrahmanyam Vinjamuri, Surya Narayana Devarakonda, Sesha Reddy Yarraguntla, Vamsi Krishna Mudapaka, Venu Nalivela
  • Glycoside derivatives and uses thereof
    Patent number: 8466114
    Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: June 18, 2013
    Assignee: Novartis AG
    Inventors: Gregory Raymond Bebernitz, Mark G. Bock, Dumbala Srinivas Reddy, Atul Kashinath Hajare, Vinod Vyavahare, Sandeep Bhausaheb Bhosale, Suresh Eknath Kurhade, Videsh Salunkhe, Nadim S. Shaikh, Debnath Bhuniya, P. Venkata Palle, Lili Feng, Jessica Liang
  • Glycoside derivative and uses thereof
    Patent number: 8394772
    Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: March 12, 2013
    Assignee: Novartis AG
    Inventors: Gregory Raymond Bebernitz, Mark Gary Bock, Debnath Bhuniya, Laxmikant Datrange, Suresh Eknath Kurhade, P. Venkata Palle, Dumbala Srinivas Reddy
  • GLYCOSIDE DERIVATIVES AND USES THEREOF
    Publication number: 20130017993
    Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 17, 2013
    Applicant: NOVARTIS AG
    Inventors: Gregory Raymond BEBERNITZ, Mark G. BOCK, Dumbala Srinivas REDDY, Atul Kashinath HAJARE, Vinod VYAVAHARE, Sandeep Bhausaheb BHOSALE, Suresh Eknath KURHADE, Videsh SALUNKHE, Nadim S. SHAIKH, Debnath BHUNIYA, P. Venkata PALLE, Lili FENG, Jessica LIANG
  • Aadenosine receptor antagonists
    Patent number: 8324224
    Abstract: Disclosed are novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.
    Type: Grant
    Filed: June 27, 2011
    Date of Patent: December 4, 2012
    Assignee: Gilead Sciences, Inc.
    Inventors: Rao Kalla, Thao Perry, Elfatih Elzein, Vaibhav Varkhedkar, Xiaofen Li, Prabha Ibrahim, Venkata Palle, Dengming Xiao, Jeff Zablocki
  • Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application
    Patent number: 8299115
    Abstract: Pyrrole-2-carboxamide derivatives, their polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts and formulations thereof, beneficial for prophylaxis, management, treatment, control of progression, or adjunct treatment of diseases and/or medical conditions where the activation of glucokinase would be beneficial, are disclosed. The disclosure also provides process of preparation of these pyrrole-2-carboxamides.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: October 30, 2012
    Inventors: Debnath Bhuniya, S. Gobind Kapkoti, S. Jayakumar Warrier, Gagan Kukrejka, N. Jagadeesh Mavinahalli, P. Venkata Palle, A. Kasim Mookhtiar
  • N-pyrazole A2A receptor agonists
    Patent number: 8278435
    Abstract: The present disclosure provides a process for the preparation of 2-adenosine N-pyrazole compounds exemplified by the structure shown below that are potent and selective agonists for A2A adenosine receptor, compositions comprising these compounds, and methods for using these compounds to stimulate mammalian coronary vasodilation for imaging the heart.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: October 2, 2012
    Assignee: Gilead Sciences, Inc.
    Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata Palle, Luiz Belardinelli
  • Glycoside derivatives and uses thereof
    Patent number: RE49080
    Abstract: This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: May 24, 2022
    Assignee: Novartis AG
    Inventors: Gregory Raymond Bebernitz, Mark G. Bock, Dumbala Srinivas Reddy, Atul Kashinath Hajare, Vinod Vyavahare, Sandeep Bhausaheb Bhosale, Suresh Eknath Kurhade, Videsh Salunkhe, Nadim S. Shaikh, Debnath Bhuniya, P. Venkata Palle, Lili Feng, Jessica Liang